CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Sitravatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04518046
NCT04518046Phase 1Completed
CompareCT.gov

A Phase 1/1b Study of Sitravatinib in Combination With Nivolumab and Ipilimumab in Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Mirati Therapeutics Inc.·interventional·Posted Aug 19, 2020·Updated Jun 5, 2024

In Brief

A Phase 1 clinical trial evaluating Sitravatinib, Nivolumab, and 1 other intervention for Clear-Cell Renal Cell Carcinoma. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClear-Cell Renal Cell Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedAug 19, 2020
Enrollment StartAug 11, 2020
Primary CompletionJun 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.9 years ago

Interventions

Sitravatinibdrug

Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

Nivolumabdrug

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Ipilimumabdrug

Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody